TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC

Yuntao Wang, Yi Liu, Xiaohua Li, Wei‐Ming Li, Zhihong Xue, Xiaoqian He, Weijie Xiong, Lang He, Yifeng BaiFrontiers in Pharmacology 2022 · DOI

TL;DR

This study identifies a "TCR coexpression signature" as a promising biomarker for predicting how well non-small cell lung cancer (NSCLC) patients will respond to immunotherapy. Patients with a high TCR coexpression signature tend to have better outcomes and a more favorable tumor immune microenvironment, suggesting it could help personalize treatment strategies.

What Problem Does This Paper Address?

Lung cancer remains a leading cause of cancer-related deaths, and while immune checkpoint inhibitors (ICIs) have revolutionized treatment for non-small cell lung cancer (NSCLC), a significant challenge persists: identifying which patients will truly benefit from these therapies. The effectiveness of ICIs is highly variable, and the lack of reliable biomarkers makes it difficult to optimize treatment and avoid unnecessary side effects for non-responders. This paper aims to address this gap by investigating the role of the T cell receptor (TCR) coexpression signature as a predictive biomarker for immunotherapy response in NSCLC. The TCR is crucial for immune cells to recognize and attack cancer cells, making its expression patterns a potential key to understanding treatment efficacy.

Methods

The researchers employed a multi-pronged approach to analyze the relationship between TCR coexpression and immunotherapy outcomes. They utilized:

  • Univariate COX regression, logistics regression, and Kaplan-Meier (KM) survival analysis: These standard statistical methods were used to evaluate the association between the TCR coexpression signature and patient prognosis (survival and progression-free survival) in immunotherapy-treated cohorts.
  • CIBERSORT algorithm: This computational tool was used to deconvolve gene expression data and estimate the abundance of various immune cell types within the tumor microenvironment (TIME). This allowed the researchers to compare the immune cell composition between patients with high and low TCR coexpression signatures.
  • Gene Set Enrichment Analysis (GSEA) and single-sample GSEA (ssGSEA): These algorithms were employed to analyze the activity of specific biological pathways and gene sets within the tumor samples. This helped to understand the functional consequences of different TCR coexpression levels on the tumor's immune landscape.

Datasets

The study utilized several publicly available datasets:

  • ICI-NSCLC cohort (GSE136961): This dataset specifically contained NSCLC patients who received anti-PD-1 immunotherapy, along with their clinical prognosis and gene expression data.
  • TCGA-LUAD and TCGA-LUSC cohorts: These datasets provided gene expression and clinical data for lung adenocarcinoma and lung squamous cell carcinoma, respectively, which were combined to form a "TCGA-NSCLC" cohort for broader analysis.
  • ICI-Melanoma cohort (GSE35640): This melanoma cohort treated with ICIs was used as a validation dataset due to the scarcity of NSCLC cohorts with both ICI treatment and expression data.
  • ICI-BLCA cohort: An open-source bladder cancer cohort treated with ICIs was also included for further validation.

Key Insights and Ideas

  • TCR Coexpression as a Prognostic Indicator: The most significant insight is that a high TCR coexpression signature isn't just correlated with better outcomes, but it can actively predict them. This moves beyond simple correlation to suggesting a functional role.
  • Beyond Just "More T Cells": The study doesn't just find that high TCR coexpression means more T cells. It highlights a specific type of immune environment: one rich in activated immune cells (like CD8+ T cells, activated CD4+ T cells, and M1 macrophages) and pathways that promote anti-tumor activity.
  • Immune Checkpoint Molecules are Downregulated: Interestingly, patients with a high TCR coexpression signature showed lower expression of key immune checkpoint molecules (like PD-1, CTLA-4, LAG3). This suggests that a robust TCR signature might be associated with a less "suppressed" immune response, making ICIs potentially more effective.
  • Activated Signaling Pathways: The high TCR coexpression group exhibited significantly activated pathways related to lymphocyte activation, chemokine binding, and inflammatory cytokine production. This points to a more dynamic and responsive immune system within these tumors.

Key Results

  • Predictive Power: Univariate Cox regression analysis in the ICI-NSCLC cohort showed that the TCR coexpression signature could be used as a clinical prognostic indicator for immunotherapy (p = 0.0205).
  • Improved Survival: Patients with a high TCR coexpression signature in the NSCLC group had significantly improved progression-free survival (PFS) (p = 0.014).
  • Favorable Immune Microenvironment: In the ICI treatment cohort (GSE35640), a high TCR coexpression signature was associated with a high infiltration of CD8+ T cells, activated memory CD4+ T cells, and M1 macrophages.
  • Activated Pathways: Pathway enrichment analysis revealed significantly activated signal pathways related to lymphocyte proliferation, activation, chemokine binding, and inflammatory cytokine production in patients with high TCR coexpression.
  • Elevated T Cell Inflammation GEP: Patients with a high TCR coexpression signature also showed an elevated T cell inflammation gene expression profile (GEP).

Limitations and Future Work

  • Limited NSCLC Cohorts: The authors acknowledge that NSCLC cohorts with both immunotherapy prognosis data and expression data are rare. This led to the reliance on a single NSCLC cohort and the use of other cancer immunotherapy cohorts (melanoma, bladder cancer) for validation. Future work should focus on collecting more NSCLC-specific data.
  • ssGSEA for TCR Coexpression: Only ssGSEA was used to estimate TCR coexpression. Exploring other methods could provide a more comprehensive understanding.
  • TCR Diversity vs. Coexpression: The relationship between TCR diversity (e.g., number of clonal species) and the TCR coexpression signature is not fully established. Further research is needed to explore this connection and its potential mechanistic implications.
  • Mechanism Exploration: The study highlights correlations and associations, but a deeper exploration of the precise mechanisms by which TCR coexpression influences the TIME and immunotherapy response is warranted.

The authors suggest that future research should continue to collect data on NSCLC patients receiving immunotherapy to further validate the relationship between TCR coexpression and predicted prognosis. They also aim to comprehensively explore the potential mechanisms linking TCR coexpression signatures to immunotherapy outcomes.

Summary updated

Abstract

<b>Background</b>: Lung cancer has the highest morbidity and mortality rate among types of malignant tumors, and as such, research into prolonging the survival time of patients is vital. The emergence of immune checkpoint inhibitors (ICIs) has greatly improved the survival of patients with non-small cell lung cancer (NSCLC), however, the lack of effective biomarkers to predict the prognosis of immunotherapy has made it difficult to maximize the benefits. T cell receptor (TCR) is one of the most important components for recognizing tumor cells, and with this study we aim to clarify the relationship between TCR coexpression and the prognosis of NSCLC patients receiving immunotherapy. <b>Methods</b>: Univariate COX regression, logistics regression, and KM survival analysis were used to evaluate the relationship between TCR coexpression and the prognosis of immunotherapy. Additionally, CIBERSORT, Gene Set Enrichment Analysis (GSEA), and single-sample GSEA (ssGSEA) algorithms were used to evaluate the tumor immune microenvironment (TIME) of NSCLC patients. <b>Results</b>: Univariate Cox regression analysis showed that the TCR coexpression signature can be used as a clinical prognostic indicator for NSCLC patients receiving immunotherapy (<i>p</i> = 0.0205). In addition, those in the NSCLC group with a high TCR coexpression signature had significantly improved progression-free survival (PFS) (<i>p</i> = 0.014). In the ICI treatment cohort (GSE35640). In addition, there was a high infiltration of CD8+T cells, activated memory CD4+T cells, and M1 macrophages in the TIME of those with a high TCR coexpression signature. The results of pathway enrichment analysis showed that patients with a high TCR coexpression signature had significantly activated signal pathways such as lymphocyte proliferation and activation, chemokine binding, and inflammatory cytokine production. Also, we found that patients with a high TCR coexpression signature had an elevated T cell inflammation gene expression profile (GEP). <b>Conclusion</b>: We show that the TCR coexpression signature may be useful as a new biomarker for the prognosis of NSCLC patients undergoing immunotherapy, with high signatures indicating better treatment response. Additionally, we found that patients with a high TCR coexpression signature had tumor immune microenvironments with beneficial anti-tumor characteristics.
BibTeX
@inproceedings{wang2022tcr,
  author = {Yuntao Wang and Yi Liu and Xiaohua Li and Wei‐Ming Li and Zhihong Xue and Xiaoqian He and Weijie Xiong and Lang He and Yifeng Bai},
  title = {{TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.875149},
}
Figure